Table 5.

Survival of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.

Variable	ITT (n=36)	Surgery (n=23)
OS (month), median (95% CI)	31.4 (19.0-NE)	45.0 (22.6-NE)
1-year OS rate, % (95% CI)	85.8 (69.1–93.8)	95.7 (72.9–99.4)
3-year OS rate, % (95% CI)	42.2 (23.8–59.6)	52.6 (26.6–73.2)
PFS (month), median (95% CI)	19.0 (11.6–43.6)	31.4 (10.4-NE)
1-year PFS rate, % (95% CI)	68.1 (49.8–80.9)	67.1 (43.1–82.8)
3-year PFS rate, % (95% CI)	38.3 (21.5–54.9)	45.8 (23.2–65.8)

CI – confidence interval; ITT – intention-to-treat; NA – not applicable; NE – not evaluated; OS – overall survival; PFS – progression-free survival.